A Phase II Open Label Multi-Dose Study of 89Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors.
Recruiting
18 years - 99 years
All
Phase
2
20 participants needed
1 Location
Brief description of study
The research study is being conducted to test a new investigational imaging agent called
89Zr-Df-IAB22M2C with positron emission tomography/computed tomography
(PET/CT) scans on subjects with cancer who plan to be treated as part of the clinical care.
The imaging agent could help the doctor see where your CD8+ T cells are located, which
may help her/him understand your disease and your treatment response better.
If you agree to join the study, you will be asked to complete the following research
procedures: a diagnostic CT or MRI or FDG-PET scan, fresh tumor biopsy (prior to and
5-7 weeks after start of cancer treatment), 89Zr-Df-IAB22M2C infusion and 89Zr-DfIAB22M2C PET/CT scans.
Detailed description of study
Your active participation will last for approximately 16 weeks. We will conduct up to one year follow up after start of your cancer treatment. You will not need to undergo any additional research study procedures during this extended follow-up period.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Oncology,cancer
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832548
Find a site
,
Your Information has been sent successfully.
Send a message
Enter your contact details to connect with study team
Primary Contact
